BR9916220A - Derivados de arilpiperidina e aril-1,2,5,6-tetraidropiridina uréia tendo atividade de receptor 5ht1a - Google Patents

Derivados de arilpiperidina e aril-1,2,5,6-tetraidropiridina uréia tendo atividade de receptor 5ht1a

Info

Publication number
BR9916220A
BR9916220A BR9916220-2A BR9916220A BR9916220A BR 9916220 A BR9916220 A BR 9916220A BR 9916220 A BR9916220 A BR 9916220A BR 9916220 A BR9916220 A BR 9916220A
Authority
BR
Brazil
Prior art keywords
tetrahydropyridine
aryl
receptor activity
urea derivatives
arylpiperidine
Prior art date
Application number
BR9916220-2A
Other languages
English (en)
Inventor
Michael Gerard Kelly
Gan Zhang
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of BR9916220A publication Critical patent/BR9916220A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

Patente de Invenção: <B>"DERIVADOS DE ARILPIPERIDINA E ARIL-1,2,5,6-TETRAIDROPIRIDINA URéIA TENDO ATIVIDADE DE RECEPTOR 5HT1A"<D>. Compostos da fórmula (A) são úteis para o tratamento de distúrbios do sistema nervoso central, incluindo ansiedade, depressão, pânico, consumo de drogas e álcool, disfunção sexual, enxaqueca, obesidade, distúrbios cognitivos e doenças neurodegenerativas.
BR9916220-2A 1998-12-17 1999-12-16 Derivados de arilpiperidina e aril-1,2,5,6-tetraidropiridina uréia tendo atividade de receptor 5ht1a BR9916220A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21334098A 1998-12-17 1998-12-17
PCT/US1999/029907 WO2000035875A1 (en) 1998-12-17 1999-12-16 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity

Publications (1)

Publication Number Publication Date
BR9916220A true BR9916220A (pt) 2001-09-11

Family

ID=22794731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916220-2A BR9916220A (pt) 1998-12-17 1999-12-16 Derivados de arilpiperidina e aril-1,2,5,6-tetraidropiridina uréia tendo atividade de receptor 5ht1a

Country Status (7)

Country Link
EP (1) EP1140831A1 (pt)
JP (1) JP2002532472A (pt)
CN (1) CN1335835A (pt)
AU (1) AU3123500A (pt)
BR (1) BR9916220A (pt)
CA (1) CA2351400A1 (pt)
WO (1) WO2000035875A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106074B2 (en) 2001-07-13 2012-01-31 Pierre Fabre Medicament Pyridin-2-yl-methylamine derivatives for treating opiate dependence
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1606282B1 (en) * 2003-02-24 2008-11-12 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism
AU2003300726A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research N-aryloxypropanolyl-n'-phenethyl-urea
US6962945B2 (en) 2004-03-26 2005-11-08 Council Of Scientific And Industrial Research N-aryloxypropanolyl-N′-phenethyl-urea
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882432A (en) * 1989-01-09 1989-11-21 American Home Products Corporation Polycyclic-carbamic acid piperazinoalkyl esters and amides
FR2664592B1 (fr) * 1990-07-10 1994-09-02 Adir Nouveaux derives de la piperidine, de la tetrahydropyridine et de la pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9314758D0 (en) * 1993-07-16 1993-08-25 Wyeth John & Brother Ltd Heterocyclic derivatives
DE19615232A1 (de) * 1996-04-18 1997-10-23 Merck Patent Gmbh Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten

Also Published As

Publication number Publication date
CA2351400A1 (en) 2000-06-22
AU3123500A (en) 2000-07-03
CN1335835A (zh) 2002-02-13
JP2002532472A (ja) 2002-10-02
WO2000035875A1 (en) 2000-06-22
EP1140831A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
NO984204L (no) Nye brodannete cykliske aminosyrer som farmas°ytiske midler
BR9708200A (pt) Aminoácidos cíclicos substituídos como agentes farmacéuticos
PT888325E (pt) Novos amino acidos ciclicos como agentes farmaceuiticos
BR0317483A (pt) Derivados de benzodiazepina para o tratamento de desordens neurológicas
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
IL154082A0 (en) 3,4-dihydroisoquinoline derivative compounds and drugs containing these compounds as the active ingredient
MY124786A (en) Bis-arylsulfones
BR9809071A (pt) Agentes farmacológicos
BR9916220A (pt) Derivados de arilpiperidina e aril-1,2,5,6-tetraidropiridina uréia tendo atividade de receptor 5ht1a
DK1187832T3 (da) Aminoheterocycler, som er anvendelige som farmaceutiske midler
BR9916189A (pt) Derivados de amida arilpiperidina e aril-1,2,5,6-tetraidropiridina tendo atividade receptora 5ht1a
BR9916185A (pt) Derivados de 1,4-piperazina tendo atividade receptora de 5ht1a
BR9916263A (pt) Derivados de piperazina etilamida com atividade sobre receptor de 5-ht1a
DE69822937D1 (de) Indolmorphinan-derivate und medikamente zur behandlung/mittel zur vorbeugung von cerebralen störungen
BR0207307A (pt) Inibidores de glyt-1
DE69413554D1 (de) IMIDAZO [1,5-a] CHINOLINE ZUR BEHANDLUNG VON ANGSTZUSTÄNDEN UND SCHLAFSTÖRUNGEN
TH77753A (th) อนุพันธุ์สตาวโรสปอรินที่เป็นสารยับยั้ง flt3 รีเซพเตอร์ ไทโรซีน ไคเนส แอคติวิตี้

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.